Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?-Reference-Cited by-同舟云学术

Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?

Published:2024-05-21 Issue:1 Volume:60 Page:93-94
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Chanchlani Neil¹²,Russell Richard K.³⁴

Affiliation:

1. Department of paediatric gastroenterology, Bristol Royal Hospital for Children Bristol UK

2. Exeter Inflammatory Bowel Disease and Pharmacogenetics Group University of Exeter Exeter UK

3. Department of paediatric gastroenterology, Royal Hospital for Children and Young People Edinburgh UK

4. Child Life and Health University of Edinburgh Edinburgh UK

Abstract

LINKED CONTENTThis article is linked to Vuijk et al papers. To view these articles, visit https://doi.org/10.1111/apt.18000 and https://doi.org/10.1111/apt.18053

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18033

Reference9 articles.

1. The State of Clinical Trials in Pediatric Inflammatory Bowel Disease

2. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial

3. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study

4. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial

5. Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply;Alimentary Pharmacology & Therapeutics;2024-05-21